236 related articles for article (PubMed ID: 23725286)
21. Outcome measures for primary Sjögren's syndrome: a comprehensive review.
Seror R; Theander E; Bootsma H; Bowman SJ; Tzioufas A; Gottenberg JE; Ramos-Casals M; Dörner T; Ravaud P; Mariette X; Vitali C
J Autoimmun; 2014 Jun; 51():51-6. PubMed ID: 24411404
[TBL] [Abstract][Full Text] [Related]
22. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
[TBL] [Abstract][Full Text] [Related]
23. Emerging biological therapies in primary Sjogren's syndrome.
Ramos-Casals M; Brito-Zerón P
Rheumatology (Oxford); 2007 Sep; 46(9):1389-96. PubMed ID: 17586555
[TBL] [Abstract][Full Text] [Related]
24. B cell depletion in lupus and Sjögren's syndrome: an update.
Coca A; Sanz I
Curr Opin Rheumatol; 2009 Sep; 21(5):483-8. PubMed ID: 19644378
[TBL] [Abstract][Full Text] [Related]
25. Autoimmune diseases and Sjogren's syndrome: an autoimmune exocrinopathy.
Fox PC
Ann N Y Acad Sci; 2007 Mar; 1098():15-21. PubMed ID: 17332090
[TBL] [Abstract][Full Text] [Related]
26. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
Dörner T; Posch MG; Li Y; Petricoul O; Cabanski M; Milojevic JM; Kamphausen E; Valentin MA; Simonett C; Mooney L; Hüser A; Gram H; Wagner FD; Oliver SJ
Ann Rheum Dis; 2019 May; 78(5):641-647. PubMed ID: 30826774
[TBL] [Abstract][Full Text] [Related]
27. Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy.
Hansen A; Lipsky PE; Dörner T
Curr Opin Rheumatol; 2005 Sep; 17(5):558-65. PubMed ID: 16093833
[TBL] [Abstract][Full Text] [Related]
28. B-cell hyperactivity in primary Sjögren's syndrome.
Kroese FG; Abdulahad WH; Haacke E; Bos NA; Vissink A; Bootsma H
Expert Rev Clin Immunol; 2014 Apr; 10(4):483-99. PubMed ID: 24564507
[TBL] [Abstract][Full Text] [Related]
29. Anti-CD20 treatment in primary Sjögren's syndrome.
Isaksen K; Jonsson R; Omdal R
Scand J Immunol; 2008 Dec; 68(6):554-64. PubMed ID: 19000095
[TBL] [Abstract][Full Text] [Related]
30. Pathogenesis of Sjögren's syndrome and therapeutic consequences.
Mariette X; Gottenberg JE
Curr Opin Rheumatol; 2010 Sep; 22(5):471-7. PubMed ID: 20671520
[TBL] [Abstract][Full Text] [Related]
31. Primary Sjögren's syndrome: pathophysiological, clinical and therapeutic advances.
Gottenberg JE
Joint Bone Spine; 2009 Dec; 76(6):591-4. PubMed ID: 19932634
[TBL] [Abstract][Full Text] [Related]
32. Transfer of Sjögren's syndrome-like autoimmune lesions into SCID mice and prevention of lesions by anti-CD4 and anti-T cell receptor antibody treatment.
Hayashi Y; Haneji N; Hamano H; Yanagi K
Eur J Immunol; 1994 Nov; 24(11):2826-31. PubMed ID: 7957574
[TBL] [Abstract][Full Text] [Related]
33. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X
Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808
[TBL] [Abstract][Full Text] [Related]
34. Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome.
Daridon C; Pers JO; Devauchelle V; Martins-Carvalho C; Hutin P; Pennec YL; Saraux A; Youinou P
Arthritis Rheum; 2006 Jul; 54(7):2280-8. PubMed ID: 16802367
[TBL] [Abstract][Full Text] [Related]
35. [Primary Sjögren's syndrome--more than a dry mouth and dry eyes].
Magnus JH; Omdal R; Hinderaker W; Husby G
Nord Med; 1990; 105(10):262-3. PubMed ID: 2235472
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab.
Ahmadi-Simab K; Lamprecht P; Nölle B; Ai M; Gross WL
Ann Rheum Dis; 2005 Jul; 64(7):1087-8. PubMed ID: 15958765
[No Abstract] [Full Text] [Related]
37. Rituximab in primary Sjögren's syndrome: a ten-year journey.
Carubbi F; Alunno A; Cipriani P; Bartoloni E; Ciccia F; Triolo G; Gerli R; Giacomelli R
Lupus; 2014 Nov; 23(13):1337-49. PubMed ID: 25096066
[TBL] [Abstract][Full Text] [Related]
38. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
Hamza N; Bootsma H; Yuvaraj S; Spijkervet FK; Haacke EA; Pollard RP; Visser A; Vissink A; Kallenberg CG; Kroese FG; Bos NA
Ann Rheum Dis; 2012 Nov; 71(11):1881-7. PubMed ID: 22615459
[TBL] [Abstract][Full Text] [Related]
39. Biologic treatment in Sjögren's syndrome.
Sada PR; Isenberg D; Ciurtin C
Rheumatology (Oxford); 2015 Feb; 54(2):219-30. PubMed ID: 25342375
[TBL] [Abstract][Full Text] [Related]
40. The weight of interleukin-6 in B cell-related autoimmune disorders.
Youinou P; Jamin C
J Autoimmun; 2009; 32(3-4):206-10. PubMed ID: 19307104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
